Derris Scandens: The Different Plant Jewel Vine Gets Confused With
Every other article in this Benefits leg exists because of this one. If you searched for "Derris" hoping to find a joint-pain remedy, an anti-inflammatory, or a traditional Thai medicine, you were not wrong to look — you were one species off. Derris scandens is a real medicinal plant: randomised controlled trials against knee osteoarthritis, a systematic review and meta-analysis of its clinical evidence, and a place on Thailand's National List of Essential Medicines. Derris elliptica — jewel vine, the subject of this site's main page — is the fish poison that trained rotenone's reputation as a laboratory tool for destroying dopamine neurons. They are different plants, in the same genus, sharing a common naming pattern that has done real, documented damage to both of their reputations. This article exists to make sure that damage stops at your search results.
Table of Contents
- The Short Answer
- Two Plants, One Genus, Very Different Chemistry
- What Derris scandens Actually Is: Thai Traditional Medicine
- The Clinical Evidence: The Osteoarthritis Trial
- The Systematic Review and Meta-Analysis
- Mechanism: Isoflavonoids, Not Rotenoids
- Modern Chemistry and Quality-Control Literature
- Thailand's National List of Essential Medicines: What That Status Means
- Immune and Other Pharmacology
- Real-World Confusion Risk: How a Buyer Ends Up With the Wrong Species
- The Marker-Compound Caveat
- What This Page Is Not Claiming
- What a Buyer Can Actually Do
- Numbered Findings: What Is Not Known
- Key Research Papers
- External Resources
- Connections
The Short Answer
Derris scandens (Roxb.) Benth. — Thai: thao wan priang — is a woody climbing legume, in the same genus as jewel vine, used in Thai traditional medicine for musculoskeletal pain and inflammation. Unlike Derris elliptica, it has been through randomised placebo- and comparator-controlled human trials, a published systematic review and meta-analysis of those trials, and formal inclusion on Thailand's National List of Essential Medicines as a standardised herbal preparation for musculoskeletal pain. Its chemistry is dominated by isoflavonoids — not the rotenoids that define Derris elliptica — which is the chemical reason its risk profile and its evidence base look nothing alike. If a product, a website or a supplement label says only "Derris" without a species name, you cannot tell which of these two plants — or which mixture of the two — you are looking at, and that is precisely the problem this article exists to explain.
Two Plants, One Genus, Very Different Chemistry
Derris is a genus of roughly 40–50 woody climbing legumes (Fabaceae) distributed across tropical Asia, Australia and the Pacific. Botanically, sharing a genus means sharing a relatively recent common ancestor and a broadly similar growth habit — it does not mean sharing a chemical profile, a traditional use, or a safety record, any more than sharing the genus Prunus makes an almond and a cherry pit equally safe to eat. Derris elliptica and Derris scandens are exactly this kind of case:
| Derris elliptica | Derris scandens | |
|---|---|---|
| Common names | Jewel vine, tuba root, derris root, akar tuba | Thai jewel vine (in some English-language sources), thao wan priang |
| Dominant chemistry | Rotenoids (rotenone, deguelin, tephrosin) | Isoflavonoids (scandenin, lupinifolin, genistein glycosides) |
| Documented traditional use | External: fish poison, insecticide, ectoparasiticide | Internal: musculoskeletal pain, anti-inflammatory |
| Modern regulatory status | Withdrawn or restricted pesticide in most jurisdictions | Listed herbal medicine, Thailand National List of Essential Medicines |
| Human trial evidence | None located for internal use; poisoning case reports only | Randomised controlled trials; systematic review and meta-analysis |
The single English common name "jewel vine" is itself part of the problem: it has been applied loosely across the genus, so an English-language source using that name alone tells you almost nothing about which species is meant. The same is true, more consequentially, of the bare word "Derris" on a supplement label.
What Derris scandens Actually Is: Thai Traditional Medicine
Derris scandens is used in Thai traditional medicine as an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs) for low back pain and osteoarthritis, typically prepared as a dried stem powder or a hydroethanolic (water-and-alcohol) stem extract. A 2003 Journal of Ethnopharmacology study evaluating plants used in Thailand to treat arthritis included D. scandens among four species with genuine anti-inflammatory activity in laboratory testing, situating it within a broader, still-active Thai ethnopharmacological research tradition rather than as an isolated folk claim.
The plant part used matters here, as it does throughout this Benefits leg: Thai traditional and modern pharmaceutical preparations are consistently made from the stem, not the root. This is a genuine, structurally important difference from Derris elliptica, where the root is the part traded and where rotenone concentrates.
The Clinical Evidence: The Osteoarthritis Trial
Kuptniratsaikul and colleagues, publishing in the Journal of Alternative and Complementary Medicine in 2011, evaluated the efficacy and safety of a Derris scandens extract in patients with knee osteoarthritis, with naproxen — a standard NSAID — as the active comparator. This is a genuine head-to-head clinical trial against a real drug, not a placebo-only or uncontrolled design, and it is the single most-cited piece of human evidence for this plant. It is also, appropriately, a modest trial by the standards of a fully established pharmaceutical: single-center work in a specific patient population, and like most botanical-versus-drug comparator trials, it invites the general caution that a comparator trial can show two treatments performing similarly without either being proven highly effective in absolute terms. Read in full on PubMed rather than taking a summary's word for the effect size.
The Systematic Review and Meta-Analysis
Puttarak, Sawangjit and Chaiyakunapruk, publishing in the Journal of Ethnopharmacology in 2016, conducted a systematic review and meta-analysis specifically of randomised controlled trials of Derris scandens for musculoskeletal pain. A systematic review and meta-analysis is a meaningfully higher tier of evidence than any single trial — it exists specifically to check whether an individual positive result (like Kuptniratsaikul's) replicates and pools consistently across the available trial base, rather than being one favourable outlier. That this level of evidence synthesis exists at all for Derris scandens, and does not exist in any form for Derris elliptica, is one of the clearest single facts distinguishing the two species' evidence bases.
As with any meta-analysis of a botanical with a modest total trial count, the appropriate reading is "the best currently available synthesis of a real but still-limited evidence base," not "definitively proven." Read the review directly for its stated confidence intervals, heterogeneity assessment and included-trial count rather than relying on a one-line summary.
Mechanism: Isoflavonoids, Not Rotenoids
The chemistry underneath Derris scandens' anti-inflammatory reputation is a genuinely different molecular family from the rotenoids that define Derris elliptica, and getting this distinction right matters for more than taxonomy — it is the reason the two species have such different risk profiles.
A 2004 Planta Medica paper isolated anti-inflammatory isoflavonoids from the stems of Derris scandens. More recent work has continued this line directly: a 2024 Planta Medica study identified the major bioactive anti-inflammatory compounds of D. scandens stem using RAW 264.7 macrophage-like cells, showing inhibition of nitric oxide production — a standard marker of macrophage-driven inflammation — and a 2026 Scientifica paper compared the phytochemistry of D. scandens leaves and stems geographically, again assessing nitric oxide inhibitory activity. A 2023 study in the Journal of Ayurveda and Integrative Medicine extended the anti-inflammatory finding to human HaCaT keratinocytes exposed to narrowband-UVB, and a 2025 PLoS One paper reported anti-arthritic and endothelial-protective effects of a D. scandens extract in a rat model of adjuvant-induced arthritis — a genuine in vivo disease model, not only a cell-culture assay.
One naming trap is worth flagging explicitly, because it runs in exactly the direction this article is trying to prevent. Among the named constituents isolated from Derris scandens are compounds called scandenin and scandenone — and a 2011 Journal of Agricultural and Food Chemistry paper found that several D. scandens-derived constituents, including these, do have measurable insecticidal (vapor-phase) toxicity against stored-product pests. It would be easy to read "scandenin has insecticidal activity" and conclude that Derris scandens therefore shares jewel vine's rotenoid chemistry after all. It does not: scandenin and scandenone are prenylated isoflavonoids, a structurally distinct chemical class from rotenone and the other rotenoids, and their insecticidal action is a separate, unrelated piece of plant chemical defence — a great many plants, including ones eaten daily, produce some insect-deterrent compound as part of normal defensive chemistry. The clinically relevant, human-trial-tested pharmacology of D. scandens is its isoflavonoid anti-inflammatory action, not this incidental insecticidal finding, and the resemblance between "scandenin" and "rotenone" is a name coincidence, not a chemical one.
Modern Chemistry and Quality-Control Literature
Derris scandens has an active, ongoing phytochemistry research programme that jewel vine simply does not have. Isoflavones continue to be isolated and characterised: a 2020 Phytochemistry paper reported three new isoflavones from D. scandens with cancer chemopreventive and antiproliferative activity in vitro, and a 2022 Natural Product Research paper reported four more new isoflavones with in vitro antiproliferative effects. A 2020 Journal of Ethnopharmacology screening study of Sri Lankan medicinal plants specifically targeted and isolated antimicrobial flavonoids from D. scandens, extending its documented pharmacology beyond pain and inflammation. A 2022 Journal of Advanced Pharmaceutical Technology and Research paper reported wound-healing activity alongside quantification of the extract's bioactive compounds.
Two analytical papers matter specifically for quality control and identity verification — the practical question a buyer actually faces. A 2016 Phytochemical Analysis paper developed an enzyme-linked immunosorbent assay (ELISA) for genistein 7-O-[α-rhamnopyranosyl-(1→6)]-β-glucopyranoside — a specific genistein glycoside — in D. scandens, using a polyclonal antibody, and a 2019 Journal of Immunoassay and Immunochemistry paper developed a monoclonal-antibody-based ELISA for the same purpose, explicitly for quality control of commercial D. scandens material. This genistein glycoside is the compound named as the standardisation marker in the Thai Herbal Pharmacopoeia monograph for D. scandens — meaning that, unlike jewel vine, there is a real, published, laboratory-usable identity and potency marker for this plant, developed specifically because Thai regulators and manufacturers needed one.
Thailand's National List of Essential Medicines: What That Status Means
This site's evidence doctrine insists that a regulatory or formulary listing be read for what it actually certifies, not treated as a stamp of proven efficacy by itself. Applied honestly here: Thailand's National List of Essential Medicines includes standardised Derris scandens preparations — dried stem powder and a hydroethanolic stem extract — as herbal medicinal products indicated for musculoskeletal pain, and the Thai Herbal Pharmacopoeia carries a monograph for the species with the genistein-glycoside marker described above as its defined standardisation compound.
What that combination genuinely certifies: the plant's identity, its principal marker compound, and a body of supporting clinical and preclinical evidence were judged sufficient by a national regulatory body for inclusion in a formulary that Thai clinicians can prescribe from, with defined preparations rather than an undefined "extract." What it does not certify: that D. scandens is as thoroughly proven as a novel synthetic drug going through a full multi-phase trial programme, or that every product sold as "Derris scandens" outside Thailand's regulated supply chain matches the standardised preparations the listing actually covers. A National List of Essential Medicines entry is real, meaningful regulatory recognition of a specific, defined article — it is not a blanket endorsement of anything a label happens to call by the same name, which is precisely the gap the next two sections address.
Immune and Other Pharmacology
Beyond the musculoskeletal-pain literature, Derris scandens has a scattered but real record of other pharmacological investigation, each item worth labelling precisely for what kind of evidence it is rather than folding into a general "also good for the immune system" claim.
Sriwanthana and Chavalittumrong, in a 2001 Journal of Ethnopharmacology paper, investigated the effect of a D. scandens hydroalcoholic extract on lymphocyte proliferation and natural killer (NK) cell activity using peripheral blood mononuclear cells (PBMC) from both healthy donors and HIV-1-infected patients, finding a concentration-dependent enhancement of NK cell function and induction of interleukin-2 secretion. This is genuine immunopharmacology — and it is in vitro human cell work, not a clinical trial in living patients; it shows the extract does something measurable to isolated immune cells in a dish, which is a meaningfully different claim from showing it improves immune outcomes in a person. A separate line of work has explored D. scandens extracts and isolated isoflavones for antiproliferative and cancer-chemopreventive activity in cell lines, and one 2012 Asian Pacific Journal of Cancer Prevention paper found that a D. scandens extract potentiated radioresistance of Hep-2 laryngeal cancer cells in vitro — a finding worth flagging as a caution rather than a benefit: if this in vitro effect held any relevance in vivo, it would argue for caution around this extract in anyone undergoing radiotherapy, not for a general "anticancer" framing.
Real-World Confusion Risk: How a Buyer Ends Up With the Wrong Species
The mechanisms are mundane, and the parent page for jewel vine already names most of them in general terms. Applied specifically to the elliptica/scandens pair:
- Genus-level indexing. Ethnobotanical and supplement-ingredient databases that aggregate at the genus level inherit D. scandens' clinical trial record and NLEM status for every species called "Derris," jewel vine included.
- Shared common-name conventions. "Jewel vine" has been applied loosely across the genus in English-language sources. A search for "jewel vine benefits" can surface content about either species without the reader realising a species boundary has been crossed.
- Wild-harvest supply chains without species-level authentication. Both species are woody climbers with broadly similar habit, harvested from overlapping regions of Southeast Asia. A collector paid by weight, and an intermediary further down the chain, may not reliably distinguish them, particularly once material is chipped or powdered.
- Content scraping and citation drift. A supplement or blog page citing "Derris" research copies a citation for D. scandens' trial evidence onto a product that may not specify, or may not actually contain, that species.
The consequence runs in one specific, serious direction: a buyer seeking the real, trial-supported anti-inflammatory plant can end up with unauthenticated material that may be jewel vine, may be a mixture, or may simply be mislabelled — receiving none of D. scandens' documented benefit and inheriting, however diluted, the chemistry the parent page describes at length.
The Marker-Compound Caveat
The genistein-glycoside ELISA methods described above are real, useful, and worth one honest qualification. A marker-compound assay, standing alone, is fundamentally a potency and quality-control check, built and validated by a laboratory that already knows it is testing Derris scandens material — it confirms how much of a defined marker compound a known-source sample contains. It is a different tool from a species-identity test, which has to work on an unknown sample and rule out related species that might share the same or a similar marker.
Applied here, this cuts in D. scandens' favour more than it does for many herbs on this site: unlike a fully pan-plant marker such as beta-sitosterol, the specific genistein glycoside used in the Thai Herbal Pharmacopoeia monograph is a more distinctive marker, and a manufacturer running the published ELISA on verified source material has a real, workable quality-control tool. What it does not do is help an ordinary buyer looking at a finished product on a shelf: unless the seller states that this specific assay was run, and on material already confirmed by botanical or genetic identification to be D. scandens rather than a related species, "standardised extract" on a label is not the same claim as "identity-verified." The distinction matters most exactly where this article's whole argument lives — at the point of purchase, not in the laboratory that developed the assay.
What This Page Is Not Claiming
Refusing to overstate runs in both directions, and it is worth being explicit about what this article is not saying:
- This is not a claim that Derris scandens is definitively proven or risk-free. Its trial base is real but modest in size; more, larger, and independently replicated trials would strengthen the evidence considerably. Anyone considering it, particularly alongside NSAIDs or other anti-inflammatory medications, should discuss it with a clinician rather than treating a website summary as sufficient.
- This is not an endorsement of any specific commercial product. This site does not evaluate or recommend individual supplement brands, and nothing here should be read as confirming that a particular product on a shelf is genuine, correctly dosed, or free of the confusion described above.
- The radioresistance-potentiation finding is a single in vitro result, not an established clinical hazard — it is reported here as a reason for caution and further study, not as a proven danger.
- None of this reflects on Derris elliptica in the other direction either. Nothing about D. scandens being a real medicine makes jewel vine safer, and nothing on this page should be read as softening the parent page's warning.
What a Buyer Can Actually Do
- Insist on the full binomial and plant part on the label — "Derris scandens stem extract" is a checkable claim; "Derris extract" is not, and should be refused outright given what is at stake in this specific genus.
- Prefer products sourced through, or explicitly referencing, Thailand's regulated herbal-medicine supply chain — the National List of Essential Medicines and Thai Herbal Pharmacopoeia framework, where the standardisation and identity infrastructure described above actually operates.
- Ask whether identity, not just potency, was verified, and by what method. A certificate of analysis reporting only a marker-compound assay has not established species identity on its own; ask specifically whether botanical or DNA-based authentication was also performed.
- Treat "Derris" alone, with no species name, as a refusal-worthy label — given that the other species sharing this genus and this common name is a withdrawn pesticide and a documented human poison, this is one case where the stakes of a missing species name are unusually high.
- Discuss use alongside existing NSAIDs or anti-inflammatory medication with a clinician, since the trial evidence for D. scandens comes from comparator-controlled settings, not from combination use.
Numbered Findings: What Is Not Known
- No published market survey using species-level (DNA or equivalent) identification of commercial "Derris" products has been located, so the actual rate of elliptica/scandens confusion or mixing in the open supplement market is unquantified.
- Long-term safety data for D. scandens beyond the duration of the published trials is limited. The trial base, while real, does not extend to years-long use.
- Formal drug-interaction studies for D. scandens, including with NSAIDs, anticoagulants or other common medications, were not located. "No known interactions" here reflects absent research, not a tested and confirmed absence of interaction.
- The in vitro radioresistance-potentiation finding has not been followed up in vivo, so its real-world clinical relevance, if any, is unknown.
- Pharmacokinetic data — absorption, half-life, metabolism — for D. scandens' isoflavonoids in humans was not located in the course of this research.
Key Research Papers
Every citation below links a live, pre-validated PubMed search rather than a fixed record. Species-specific queries are phrase-locked to Derris scandens specifically, to avoid pulling in Derris elliptica results through genus-level MeSH expansion — the exact failure mode this article is about.
- Kuptniratsaikul V, Pinthong T, Bunjob M, Thanakhumtorn S. Efficacy and safety of Derris scandens Benth. extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine, 2011. PubMed search.
- Puttarak P, Sawangjit R, Chaiyakunapruk N. Efficacy and safety of Derris scandens (Roxb.) Benth. for musculoskeletal pain treatment: a systematic review and meta-analysis of randomized controlled trials. Journal of Ethnopharmacology, 2016. PubMed search.
- An evaluation of the activity related to inflammation of four plants used in Thailand to treat arthritis. Journal of Ethnopharmacology, 2003. PubMed search.
- Anti-inflammatory isoflavonoids from the stems of Derris scandens. Planta Medica, 2004. PubMed search.
- Identification of major bioactive anti-inflammatory compounds of Derris scandens stem using RAW 264.7 cells. Planta Medica, 2024. PubMed search.
- Anti-arthritic and endothelial protective effects of Derris scandens extract in adjuvant-induced arthritis in rats. PLoS One, 2025. PubMed search.
- Anti-inflammatory effects of Derris scandens extract on narrowband-UVB-exposed HaCaT human keratinocytes. Journal of Ayurveda and Integrative Medicine, 2023. PubMed search.
- Vapor-phase toxicity of Derris scandens-derived constituents (including scandenin and scandenone) against stored-product pests. Journal of Agricultural and Food Chemistry, 2011. PubMed search — the source of the scandenin-naming caution above.
- Three new isoflavones from Derris scandens with cancer chemopreventive and antiproliferative activity. Phytochemistry, 2020. PubMed search.
- Development of a monoclonal-antibody-based ELISA for quality control of Derris scandens. Journal of Immunoassay and Immunochemistry, 2019. PubMed search.
- An enzyme-linked immunosorbent assay for genistein glycoside determination in Derris scandens. Phytochemical Analysis, 2016. PubMed search.
- Sriwanthana B, Chavalittumrong P. In vitro effect of Derris scandens on normal lymphocyte proliferation and its activities on natural killer cells in normals and HIV-1-infected patients. Journal of Ethnopharmacology, 2001. PubMed search.
- Derris scandens extract and potentiation of radioresistance in Hep-2 laryngeal cancer cells. Asian Pacific Journal of Cancer Prevention, 2012. PubMed search.
- Screening for bioactive secondary metabolites in Sri Lankan medicinal plants: antimicrobial flavonoids from Derris scandens. Journal of Ethnopharmacology, 2020. PubMed search.
External Resources
- WHO — Thailand National List of Essential Medicines — the formulary listing standardised Derris scandens preparations.
- Plants of the World Online (Kew) — the reference for checking current accepted names within Derris.
- PubMed — the index behind every search on this page.
- ClinicalTrials.gov — search Derris scandens for currently registered and completed trials.
- National Center for Complementary and Integrative Health — plain-language assessments of botanical evidence quality.
- United States Pharmacopeia and NSF — independent supplement verification programmes.